Everest Biotech prostate cancer antibodies
If diagnosed early, prostate cancer can be treated with surgery or radiation therapy, often alongside hormone therapy. Immunohistochemistry (IHC) is used for the diagnosis of prostate carcinoma from prostate biopsy; for this process, several IHC prostate cancer biomarkers are used.
A key biomarker is prostate-specific antigen (PSA), which is used in the PSA blood test for early detection as well as histological diagnosis. Another key biomarker is Alpha-methylacyl-CoA racemase (AMACR), which is used to determine whether the basal cell myoepithelial layer has been affected by a tumour. It has also been used in the diagnosis of prostate cancer compared to benign tumours. An additional predictive biomarker is ERG. A transcriptional regulator, ERG plays a pivotal role in the carcinogenesis of prostate cancer, as a result of several different fusions it undergoes. With the importance of biomarkers such as these, it is hoped that the discovery of new biomarkers will enable improvements to both early detection and treatments.
Everest Biotech’s prostate cancer antibodies range includes PSA, AMACR, ERG and essential biomarkers.
Phone: 02 9698 2022
Amsbio BioPORTER Protein Delivery Reagent
The BioPORTER Protein Delivery Reagent from Amsbio is a specialised, lipid-based reagent designed...
Amsbio StemFit Basic04CT stem cell medium
StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to...
Takara Bio Europe Cellartis MSC EV Wonder GMP-grade medium
Takara Bio Europe has introduced a Good Manufacturing Practice (GMP)-grade version of Cellartis...
